Clinical Trials · NCT03713684

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Name: Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 3Efpeglenatide

Phase: Phase 3
Recruitment status: Terminated
Sponsor: Sanofi
Enrollment: 370
Start date: Nov 2018
Locations: 47 sites, 3 countries
Primary endpoint: Change From Baseline to Week 30 in HbA1c

View Efpeglenatide compound reference